Pomerantz LLP Files Class Action Against LifeMD for Securities Fraud.
PorAinvest
sábado, 6 de septiembre de 2025, 10:32 am ET1 min de lectura
LFMD--
The complaint, filed by Glancy Prongay & Murray LLP, alleges that LifeMD made materially false and misleading statements and failed to disclose material adverse facts about its business, operations, and prospects during the Class Period (May 7, 2025, to August 5, 2025) [1]. Specifically, the company is accused of overstating its competitive position and being reckless in raising its 2025 guidance without properly accounting for rising customer acquisition costs in its RexMD segment. These actions, the complaint argues, led to materially misleading statements about the company’s business, operations, and prospects.
On August 5, 2025, LifeMD announced that it was revising its full-year 2025 guidance due to temporary challenges facing its Rex MD business. This announcement resulted in a significant drop in the company’s stock price, falling $5.31 per share or 44.8% to close at $6.53 per share on August 6, 2025 [1].
Pomerantz LLP, a prominent law firm known for its work in corporate and securities litigation, is also investigating claims on behalf of LifeMD investors. Pomerantz LLP has advised investors to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980, if they wish to join the class action [2].
Investors who believe they may have suffered losses due to these alleged practices are encouraged to contact Glancy Prongay & Murray LLP for more information. The firm can be reached at shareholders@glancylaw.com or by phone at 310-201-9150, toll-free at 888-773-9224. More details can be found on their website at www.glancylaw.com [1].
References:
[1] https://www.morningstar.com/news/business-wire/20250905627675/deadline-alert-lifemd-inc-lfmd-investors-who-lost-money-urged-to-contact-glancy-prongay-murray-llp-about-securities-fraud-lawsuit
[2] https://www.marketscreener.com/news/pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-lifemd-inc-lfmd-ce7d59dbd88cf326
A class-action lawsuit has been filed against LifeMD, Inc. (NASDAQ: LFMD) alleging securities fraud or other unlawful business practices. The lawsuit concerns investors who purchased LifeMD securities during the class period. Those interested in joining the class action must ask the court to appoint them as Lead Plaintiff by October 27, 2025. The complaint can be obtained at pomerantzlaw.com.
Investors of LifeMD, Inc. (NASDAQ: LFMD) are urged to take note of a significant development. A class-action lawsuit has been filed against the company, alleging securities fraud and other unlawful business practices. The lawsuit targets investors who purchased LifeMD securities during the specified class period. Those interested in joining the class action must ask the court to appoint them as Lead Plaintiff by October 27, 2025 [1].The complaint, filed by Glancy Prongay & Murray LLP, alleges that LifeMD made materially false and misleading statements and failed to disclose material adverse facts about its business, operations, and prospects during the Class Period (May 7, 2025, to August 5, 2025) [1]. Specifically, the company is accused of overstating its competitive position and being reckless in raising its 2025 guidance without properly accounting for rising customer acquisition costs in its RexMD segment. These actions, the complaint argues, led to materially misleading statements about the company’s business, operations, and prospects.
On August 5, 2025, LifeMD announced that it was revising its full-year 2025 guidance due to temporary challenges facing its Rex MD business. This announcement resulted in a significant drop in the company’s stock price, falling $5.31 per share or 44.8% to close at $6.53 per share on August 6, 2025 [1].
Pomerantz LLP, a prominent law firm known for its work in corporate and securities litigation, is also investigating claims on behalf of LifeMD investors. Pomerantz LLP has advised investors to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980, if they wish to join the class action [2].
Investors who believe they may have suffered losses due to these alleged practices are encouraged to contact Glancy Prongay & Murray LLP for more information. The firm can be reached at shareholders@glancylaw.com or by phone at 310-201-9150, toll-free at 888-773-9224. More details can be found on their website at www.glancylaw.com [1].
References:
[1] https://www.morningstar.com/news/business-wire/20250905627675/deadline-alert-lifemd-inc-lfmd-investors-who-lost-money-urged-to-contact-glancy-prongay-murray-llp-about-securities-fraud-lawsuit
[2] https://www.marketscreener.com/news/pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-lifemd-inc-lfmd-ce7d59dbd88cf326
Divulgación editorial y transparencia de la IA: Ainvest News utiliza tecnología avanzada de Modelos de Lenguaje Largo (LLM) para sintetizar y analizar datos de mercado en tiempo real. Para garantizar los más altos estándares de integridad, cada artículo se somete a un riguroso proceso de verificación con participación humana.
Mientras la IA asiste en el procesamiento de datos y la redacción inicial, un miembro editorial profesional de Ainvest revisa, verifica y aprueba de forma independiente todo el contenido para garantizar su precisión y cumplimiento con los estándares editoriales de Ainvest Fintech Inc. Esta supervisión humana está diseñada para mitigar las alucinaciones de la IA y garantizar el contexto financiero.
Advertencia sobre inversiones: Este contenido se proporciona únicamente con fines informativos y no constituye asesoramiento profesional de inversión, legal o financiero. Los mercados conllevan riesgos inherentes. Se recomienda a los usuarios que realicen una investigación independiente o consulten a un asesor financiero certificado antes de tomar cualquier decisión. Ainvest Fintech Inc. se exime de toda responsabilidad por las acciones tomadas con base en esta información. ¿Encontró un error? Reportar un problema
Comentarios
Aún no hay comentarios